Publication | Closed Access

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

ObesityMetabolic SyndromeMetabolic Associated SteatohepatitisFxr AgonistHepatologyMetabolic Associated Steatotic Liver DiseaseNonalcoholic Fatty Liver DiseaseMedicineLiver PhysiologyLiver Fat ContentHepatology InflammationNon-alcoholic SteatohepatitisHepatotoxicityLiver DiseaseFatty Liver DiseasePharmacologyDrug-induced Liver InjuryHealth Sciences